Amundi Decreases Position in Charles River Laboratories International, Inc. $CRL

Amundi trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 76.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,347 shares of the medical research company’s stock after selling 53,919 shares during the quarter. Amundi’s holdings in Charles River Laboratories International were worth $2,305,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Brooklyn Investment Group lifted its position in shares of Charles River Laboratories International by 93.5% in the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 86 shares in the last quarter. Teachers Retirement System of The State of Kentucky lifted its position in shares of Charles River Laboratories International by 2.7% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company’s stock valued at $589,000 after acquiring an additional 102 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Charles River Laboratories International by 2.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company’s stock valued at $763,000 after acquiring an additional 105 shares in the last quarter. Veracity Capital LLC lifted its position in shares of Charles River Laboratories International by 3.4% in the first quarter. Veracity Capital LLC now owns 3,298 shares of the medical research company’s stock valued at $496,000 after acquiring an additional 107 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. lifted its position in shares of Charles River Laboratories International by 6.8% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 1,926 shares of the medical research company’s stock valued at $290,000 after acquiring an additional 123 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on CRL. Redburn Atlantic upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and reduced their price objective for the company from $188.00 to $182.00 in a research report on Friday, May 23rd. Barclays upped their price objective on Charles River Laboratories International from $155.00 to $165.00 and gave the company an “equal weight” rating in a research report on Thursday, August 7th. Wall Street Zen downgraded Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 17th. Citigroup upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and upped their target price for the company from $150.00 to $200.00 in a research note on Wednesday, July 9th. Finally, Jefferies Financial Group upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and upped their target price for the company from $142.00 to $195.00 in a research note on Tuesday. Six equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $177.07.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL opened at $159.68 on Friday. The firm has a market capitalization of $7.86 billion, a PE ratio of -120.06, a P/E/G ratio of 4.90 and a beta of 1.47. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The business has a 50-day moving average of $160.86 and a two-hundred day moving average of $148.94. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $230.02.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.50 by $0.62. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm’s revenue was up .6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.80 earnings per share. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the company’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the sale, the executive vice president directly owned 24,116 shares in the company, valued at $3,800,681.60. This represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).